AU2010321773A1 - Methods and compositions for treating hedgehog-associated cancers - Google Patents

Methods and compositions for treating hedgehog-associated cancers Download PDF

Info

Publication number
AU2010321773A1
AU2010321773A1 AU2010321773A AU2010321773A AU2010321773A1 AU 2010321773 A1 AU2010321773 A1 AU 2010321773A1 AU 2010321773 A AU2010321773 A AU 2010321773A AU 2010321773 A AU2010321773 A AU 2010321773A AU 2010321773 A1 AU2010321773 A1 AU 2010321773A1
Authority
AU
Australia
Prior art keywords
cancer
inhibitor
hedgehog
tumor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010321773A
Other languages
English (en)
Inventor
John Macdougall
Karen J. Mcgovern
Veronica Travaglione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Pharmaceuticals Inc
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/762,008 external-priority patent/US20100297118A1/en
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of AU2010321773A1 publication Critical patent/AU2010321773A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010321773A 2009-11-20 2010-11-19 Methods and compositions for treating hedgehog-associated cancers Abandoned AU2010321773A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US26318409P 2009-11-20 2009-11-20
US61/263,184 2009-11-20
US29402910P 2010-01-11 2010-01-11
US61/294,029 2010-01-11
US32493410P 2010-04-16 2010-04-16
US12/762,008 2010-04-16
US12/762,008 US20100297118A1 (en) 2007-12-27 2010-04-16 Therapeutic Cancer Treatments
US61/324,934 2010-04-16
US32737310P 2010-04-23 2010-04-23
US61/327,373 2010-04-23
US33136510P 2010-05-04 2010-05-04
US61/331,365 2010-05-04
US35108210P 2010-06-03 2010-06-03
US61/351,082 2010-06-03
US38676310P 2010-09-27 2010-09-27
US61/386,763 2010-09-27
PCT/US2010/057534 WO2011063309A1 (fr) 2009-11-20 2010-11-19 Procédés et compositions de traitement de cancers associés à hedgehog

Publications (1)

Publication Number Publication Date
AU2010321773A1 true AU2010321773A1 (en) 2012-06-14

Family

ID=44060053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010321773A Abandoned AU2010321773A1 (en) 2009-11-20 2010-11-19 Methods and compositions for treating hedgehog-associated cancers

Country Status (5)

Country Link
EP (1) EP2502078A1 (fr)
JP (1) JP2013511549A (fr)
AU (1) AU2010321773A1 (fr)
CA (1) CA2781300A1 (fr)
WO (1) WO2011063309A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CA2710858A1 (fr) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Procedes de reduction stereoselective
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
WO2013106812A1 (fr) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Médicament personnalisé pour la prédiction de thérapie ciblant la voie hedgehog
WO2013148775A1 (fr) * 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Biomarqueur prédictif utile pour thérapie anticancéreuse médiée par un inhibiteur de cdk
WO2014002922A1 (fr) * 2012-06-26 2014-01-03 アステラス製薬株式会社 Méthode de traitement du cancer par l'utilisation combinée d'un agent anti-cancéreux
EP3698784A1 (fr) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Procédés de traitement du cancer du poumon
JP6387389B2 (ja) * 2013-03-13 2018-09-05 アブラクシス バイオサイエンス， エルエルシー 小児充実性腫瘍の処置の方法
EP2968191B1 (fr) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Méthodes de traitement du cancer de la vessie
WO2014177915A1 (fr) * 2013-05-01 2014-11-06 Piramal Enterprises Limited Multi-thérapie anti-cancéreuse utilisant des dérivés de imidazo[4,5-c]quinoline
EP3131552B1 (fr) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor
US10597294B2 (en) 2014-05-30 2020-03-24 Novomer, Inc. Integrated methods for chemical synthesis
CA2951587C (fr) * 2014-06-16 2021-05-25 Worldwide Innovative Network Methode de selection de tri-therapie personnalisee pour le traitement du cancer
WO2016037194A1 (fr) * 2014-09-05 2016-03-10 The Trustees Of Columbia University In The City Of New York Polythérapie à base d'inhibiteur des voies akt et shh destinée au traitement de carcinomes de cellules basales
MA41514A (fr) 2015-02-13 2017-12-19 Novomer Inc Procédés intégrés de synthèse chimique
EP3302428A1 (fr) 2015-06-04 2018-04-11 Pellepharm Inc. Formulations topiques pour l'administration de composés inhibiteurs du hérisson et leur utilisation
CN109153977B (zh) 2016-01-08 2022-11-01 雷普利穆内有限公司 溶瘤病毒株
CN107137406B (zh) * 2016-03-01 2021-07-02 江苏恒瑞医药股份有限公司 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN110123837A (zh) * 2018-02-02 2019-08-16 科济生物医药（上海）有限公司 细胞免疫治疗的组合
CA3094453A1 (fr) * 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methodes de traitement de troubles du systeme nerveux central par l'intermediaire de l'administration de nanoparticules d'un inhibiteur de mtor et d'une albumine
CN112601547A (zh) * 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
EP1888105A2 (fr) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. Vaccins p53 permettant de traiter les cancers
JP2009514874A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ及びペメトレキセドを用いて癌を治療する方法
TWI433674B (zh) * 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101663033B (zh) * 2007-04-18 2013-01-16 默沙东公司 作为smo拮抗剂的三唑衍生物

Also Published As

Publication number Publication date
EP2502078A1 (fr) 2012-09-26
WO2011063309A1 (fr) 2011-05-26
JP2013511549A (ja) 2013-04-04
CA2781300A1 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
AU2010321773A1 (en) Methods and compositions for treating hedgehog-associated cancers
US20120010229A1 (en) Therapeutic regimens for hedgehog-associated cancers
AU2019240572B2 (en) Compositions and methods for treating cancers associated with ETBR activation
EP3191097B1 (fr) Polythérapies
AU2018287519B2 (en) IL-1beta binding antibodies for use in treating cancer
US20230081191A1 (en) Conjoint therapies for immunomodulation
WO2012006589A2 (fr) Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog
KR20240097966A (ko) 암을 치료하는 방법
JP2011522773A (ja) 治療剤での癌の処置方法
JP2013510585A (ja) 癌の同定、評価、予防および治療のための組成物、キットおよび方法
US20230310437A1 (en) Ttp phosphorylation for the identification of personalized medicines
US20200289495A1 (en) Methods of inhibiting endothelin b receptor expressing tumor metastases
US20200268829A1 (en) Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer
WO2018235056A1 (fr) Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
AU2019409139A1 (en) Use of IL-1β binding antibodies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period